Actuate Therapeutics, Inc. Financing Cash Flow
Actuate Therapeutics, Inc. (ACTU) reported Financing Cash Flow of $688.87 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- Actuate Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $696.96K, a 89.72% decline year-over-year.
- Actuate Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$8.09K.
- Actuate Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$29.30K.
- Actuate Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $17.11M, a 23.35% decline year-over-year.
- Actuate Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $23.72M, a 13.81% decline from fiscal 2024.
- Actuate Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $27.53M, a 565.75% increase from fiscal 2023.
- Actuate Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $4.13M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $696.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $688.87K 10-Q · filed 2026-08-14 | $659.57K derived: sum of 3 quarters · filed 2026-08-14 | $17.77M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$8.09K 10-Q · filed 2026-05-14 | -$37.39K derived: sum of 2 quarters · filed 2026-05-14 | $17.07M derived: sum of 3 quarters · filed 2026-05-14 | $23.85M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$29.30K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $17.08M derived: sum of 2 quarters · filed 2026-03-26 | $23.86M derived: sum of 3 quarters · filed 2026-08-14 | $23.72M 10-K · filed 2026-03-26 |
| 2025-09-30 | $17.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $23.89M derived: sum of 2 quarters · filed 2026-08-14 | $23.75M 10-Q · filed 2025-11-13 | $23.64M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $6.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $6.64M 10-Q · filed 2026-08-14 | $6.53M derived: sum of 3 quarters · filed 2026-08-14 | $28.85M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$133.48K 10-Q · filed 2026-05-14 | -$242.89K derived: sum of 2 quarters · filed 2026-05-14 | $22.08M derived: sum of 3 quarters · filed 2026-05-14 | $23.03M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$109.41K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $22.21M derived: sum of 2 quarters · filed 2026-03-26 | $23.17M derived: sum of 3 quarters · filed 2026-03-26 | $27.53M 10-K · filed 2026-03-26 |
| 2024-09-30 | $22.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $23.28M derived: sum of 2 quarters · filed 2025-11-13 | $27.64M 10-Q · filed 2025-11-13 | $27.64M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $957.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $5.31M 10-Q · filed 2025-08-14 | $5.31M derived: sum of 3 quarters · filed 2025-08-14 | $5.31M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $4.36M 10-Q · filed 2025-05-15 | $4.36M derived: sum of 2 quarters · filed 2025-05-15 | $4.36M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $4.13M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $4.13M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $4.13M 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |